Volume 9, Issue 5

CFTR Beyond the Lung: Growth, Glucose Tolerance, CFLD

In this issue:

Cystic fibrosis is best known as a disease of the lungs, where CFTR modulators have been showing exceptional results in improving pulmonary function. However, ongoing research is showing that CFTR modulation can benefit critical systems throughout the body.  

In this Issue, Drs. Darla Shores and Anna Reed from the Division of Gastroenterology, Hepatology, and Nutrition at Johns Hopkins Children's Center analyze the recently published data on the effects of CFTR modulation on growth, glucose tolerance, and CF-associated liver disease. 

Learning objectives:

  • Describe how CFTR modulators may affect pancreatic endocrine and exocrine function. 
  • Explain how CFTR modulators may affect cystic fibrosis liver disease. 

Authors:

Darla Shores, MD, PhD
Darla Shores, MD, PhD

Assistant Professor of Pediatrics 
Associate Fellowship Director, Pediatric Gastroenterology 
Medical Co-Director, THRIVE Pediatric Intestinal Rehabilitation Center 
Division of Gastroenterology, Hepatology, and Nutrition 
Johns Hopkins Children's Center 
Baltimore, MD

 

 

Anna Reed, MD, MPH
Anna Reed, MD, MPH

Fellow 
Johns Hopkins Division of Gastroenterology, Hepatology, and Nutrition 
Johns Hopkins Children's Center 
Baltimore, MD

Program Directors:

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Peter J. Mogayzel, Jr., MD, PhD

Director, Eudowood Division of Pediatric Respiratory Sciences
Professor of Pediatrics
Director, Cystic Fibrosis Center

Donna Peeler, RN, BSN

Senior Clinical Nurse/Case Manager
Pediatric CF Program Coordinator
Johns Hopkins Cystic Fibrosis Center
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: June 30, 2020
Expiration date: June 29, 2022